Your browser doesn't support javascript.
loading
Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia.
Lu, Junyan; Cannizzaro, Ester; Meier-Abt, Fabienne; Scheinost, Sebastian; Bruch, Peter-Martin; Giles, Holly Ar; Lütge, Almut; Hüllein, Jennifer; Wagner, Lena; Giacopelli, Brian; Nadeu, Ferran; Delgado, Julio; Campo, Elías; Mangolini, Maurizio; Ringshausen, Ingo; Böttcher, Martin; Mougiakakos, Dimitrios; Jacobs, Andrea; Bodenmiller, Bernd; Dietrich, Sascha; Oakes, Christopher C; Zenz, Thorsten; Huber, Wolfgang.
Afiliação
  • Lu J; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Cannizzaro E; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.
  • Meier-Abt F; Department of Medical Oncology and Hematology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
  • Scheinost S; Department of Medical Oncology and Hematology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
  • Bruch PM; Molecular Therapy in Hematology and Oncology, National Center for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany.
  • Giles HA; Molecular Therapy in Hematology and Oncology, National Center for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany.
  • Lütge A; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Hüllein J; University of Heidelberg, Heidelberg, Germany.
  • Wagner L; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Giacopelli B; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.
  • Nadeu F; Department of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
  • Delgado J; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Campo E; Molecular Therapy in Hematology and Oncology, National Center for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany.
  • Mangolini M; Molecular Therapy in Hematology and Oncology, National Center for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany.
  • Ringshausen I; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
  • Böttcher M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Mougiakakos D; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Jacobs A; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Bodenmiller B; Hematopathology Unit, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
  • Dietrich S; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Oakes CC; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Zenz T; Hematopathology Unit, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
  • Huber W; Wellcome Trust/MRC Cambridge Stem Cell Institute & Department of Haematology, University of Cambridge, Cambridge CB2 0AH, UK.
Nat Cancer ; 2(8): 853-864, 2021 08.
Article em En | MEDLINE | ID: mdl-34423310
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article